학술논문
Salivary opiorphin levels in anorexia nervosa: A case-control study.
Document Type
Academic Journal
Author
Paszynska E; Department of Integrated Dentistry, Poznan University of Medical Sciences (PUMS), Poznań, Poland.; Dmitrzak-Weglarz M; Department of Psychiatry, Psychiatric Genetics Unit, PUMS, Poznań, Poland.; Roszak M; Department of Computer Science and Statistics, PUMS, Poznań, Poland.; Boucher Y; Groupe Hospitalier Pitié Salpêtrière, UFR Odontologie Université Paris Diderot, Paris, France.; Dutkiewicz A; Department of Child and Adolescent Psychiatry, PUMS, Poznań, Poland.; Tyszkiewicz-Nwafor M; Department of Child and Adolescent Psychiatry, PUMS, Poznań, Poland.; Gawriolek M; Department of Integrated Dentistry, Poznan University of Medical Sciences (PUMS), Poznań, Poland.; Otulakowska-Skrzynska J; Department of Integrated Dentistry, Poznan University of Medical Sciences (PUMS), Poznań, Poland.; Rzatowski S; Department of Integrated Dentistry, Poznan University of Medical Sciences (PUMS), Poznań, Poland.; Slopien A; Department of Child and Adolescent Psychiatry, PUMS, Poznań, Poland.
Source
Publisher: Informa Healthcare Country of Publication: England NLM ID: 101120023 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1814-1412 (Electronic) Linking ISSN: 15622975 NLM ISO Abbreviation: World J Biol Psychiatry Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: Opiorphin is a physiological inhibitor of peptidases inactivating endogenous opioids displaying strong analgesic properties without undesirable side effects, antidepressant properties or hormonal dependency. It might therefore play an important role in patients with painful diseases related to neuro-hormonal dysregulation of the nervous system, affecting saliva secretion and composition such as anorexia nervosa (AN). The main objective aim of this study was to compare the level of opiorphin in saliva of patients with AN to matched subjects free of eating disorders. Methods: A case-control clinical trial was conducted in 68 AN patients and 43 healthy matched control subjects. Depression symptoms were assessed with the self-scored questionnaire Beck Depression Inventory (BDI) and salivary samples were taken during the acute stage of AN (BMI <15 kg/m 2 ) for measuring opiorphin. Opiorphin levels were measured with a quantitative assay using a commercial immunoenzymatic Elisa kit (cat no. EH1927, Wuchan, Hubei, China). Results: No statistically significant difference was found in salivary opiorphin levels between the AN and control groups, ( P = 0.499, Mann-Whitney U -test). Positive correlations to duration of the disease, BDI and bodyweight in AN patients were evidenced. Conclusions: Measurement of salivary opiorphin levels cannot be used as a marker of AN but may allow new perspectives in monitoring AN in its early stages.